全文获取类型
收费全文 | 28259篇 |
免费 | 2583篇 |
国内免费 | 1667篇 |
专业分类
耳鼻咽喉 | 264篇 |
儿科学 | 302篇 |
妇产科学 | 344篇 |
基础医学 | 3502篇 |
口腔科学 | 449篇 |
临床医学 | 3706篇 |
内科学 | 4524篇 |
皮肤病学 | 222篇 |
神经病学 | 1827篇 |
特种医学 | 1098篇 |
外国民族医学 | 24篇 |
外科学 | 3027篇 |
综合类 | 3996篇 |
现状与发展 | 5篇 |
一般理论 | 16篇 |
预防医学 | 1910篇 |
眼科学 | 677篇 |
药学 | 2839篇 |
11篇 | |
中国医学 | 1292篇 |
肿瘤学 | 2474篇 |
出版年
2024年 | 59篇 |
2023年 | 341篇 |
2022年 | 816篇 |
2021年 | 1267篇 |
2020年 | 933篇 |
2019年 | 851篇 |
2018年 | 972篇 |
2017年 | 838篇 |
2016年 | 872篇 |
2015年 | 1285篇 |
2014年 | 1481篇 |
2013年 | 1335篇 |
2012年 | 2176篇 |
2011年 | 2234篇 |
2010年 | 1434篇 |
2009年 | 1173篇 |
2008年 | 1622篇 |
2007年 | 1671篇 |
2006年 | 1670篇 |
2005年 | 1547篇 |
2004年 | 1242篇 |
2003年 | 1254篇 |
2002年 | 1083篇 |
2001年 | 578篇 |
2000年 | 518篇 |
1999年 | 505篇 |
1998年 | 310篇 |
1997年 | 334篇 |
1996年 | 277篇 |
1995年 | 264篇 |
1994年 | 224篇 |
1993年 | 158篇 |
1992年 | 192篇 |
1991年 | 159篇 |
1990年 | 145篇 |
1989年 | 89篇 |
1988年 | 88篇 |
1987年 | 77篇 |
1986年 | 61篇 |
1985年 | 60篇 |
1984年 | 58篇 |
1983年 | 22篇 |
1982年 | 26篇 |
1981年 | 23篇 |
1980年 | 16篇 |
1979年 | 14篇 |
1978年 | 11篇 |
1977年 | 9篇 |
1974年 | 9篇 |
1973年 | 8篇 |
排序方式: 共有10000条查询结果,搜索用时 46 毫秒
71.
PET for evaluation of differential myocardial perfusion dynamics after VEGF gene therapy and laser therapy in end-stage coronary artery disease. 总被引:2,自引:0,他引:2
René A Tio Eng S Tan Gillian A J Jessurun Nic Veeger Pieter L Jager Riemer H J A Slart Richard M de Jong Jan Pruim Geke A P Hospers Antoon T M Willemsen Mike J L de Jongste Ad J van Boven Dirk J van Veldhuisen Felix Zijlstra 《Journal of nuclear medicine》2004,45(9):1437-1443
The purpose of this study was to appraise the value of PET in the assessment of the effect of supposedly proangiogenic new therapies such as gene therapy with vascular endothelial growth factor (VEGF) gene and endomyocardial laser therapy. METHODS: Thirty-five patients with end-stage coronary artery disease and class III (Canadian Cardiovascular Society) angina were included. Myocardial ischemia was evaluated with dipyridamole PET scanning and exercise tolerance with bicycle ergometry. Ten patients were treated with naked plasmid DNA encoding for human VEGF165 (VEGF) and 12 patients were treated with laser therapy (direct myocardial revascularization [DMR]) using an electromechanical mapping system. Thirteen patients were treated with standard medical therapy (control). RESULTS: In both active treatment groups, angina was reduced in most subjects, except in 2 VEGF and 5 DMR patients. In the control group, no improvement in anginal classification was found, except in 3 subjects. On the PET scan, solely in the VEGF group, the stress perfusion was significantly improved (from 57 +/- 33 to 81 +/- 55 mL/min/100 g; P = 0.031). Furthermore, in the VEGF group, the number of ischemic segments was reduced from 274 +/- 41 to 234 +/- 48 segments (P = 0.004) but not in the DMR group (from 209 +/- 43 to 215 +/- 52 segments) or in the control group (from 218 +/- 18 to 213 +/- 28 segments). Bicycle exercise duration showed slight nonsignificant changes in the VEGF group (from 3.6 +/- 2.0 to 4.6 +/- 2.1 min), in the DMR group (from 5.1 +/- 1.5 to 4.7 +/- 1.3 min), and in the control group (from 3.3 +/- 1.8 to 3.5 +/- 2.3 min). CONCLUSION: PET showed that intramyocardial gene therapy with the human VEGF165 gene in contrast to laser DMR treatment effectively reduces myocardial ischemia. 相似文献
72.
73.
74.
75.
观察18例32眼下蹲运动与高眼压的关系,分为下蹲120次,100次及80次三且,每组分别观察10眼、11眼及11眼,结果各组运动后眼压均见下降,平均为1.027±0.486kPa,1.355±0.770kPa及1.325±0.422kPa,运动前后有非常显著性差异,但各组之间差异不显著。同时观察3小时内眼压动态变化,下蹲120次组眼压下降维持时间最长,在运动后3小时与运动前眼压比较及与其余两组第3 相似文献
76.
目的:观察着色真菌蟾蜍分离株的致病性。方法:抽样取着色真菌蟾蜍分离株与标准人分离株对照,制成菌悬液,做小鼠腹腔接种,观察接种后小鼠的外观表现,做菌种逆培养和观察内脏病理变化。结果:蟾蜍分离株卡氏枝孢霉、疣状瓶霉、裴氏着色霉和甄氏外瓶霉与病人分离株一样,在接种28天后,均可从小鼠脏器逆培养出接种的菌种,并引起内脏病变,形成结核样肉芽肿,肉芽肿内均可查见棕黄色硬壳小体。而瓶霉和外瓶霉属菌种逆培养结果均阴性。结论:从野生蟾蜍分离出的卡氏枝孢霉、疣状瓶霉,裴氏着色霉和甄氏外瓶霉与病人分离株一样,对小鼠有致病性,故可能是人着色芽生菌病的致病菌。 相似文献
77.
健脾降脂颗粒中绿原酸的含量测定 总被引:1,自引:0,他引:1
目的 研究健脾降脂颗粒中绿原酸的含量测定方法。方法 采用高效液相法。色谱柱YWGC18(2 5 0mm× 4 6mm ,10 μm) ,室温 ,10 %乙腈─冰醋酸 (5∶0 1)为流动相 ,流速为 1mL/min ,检测波长 32 9nm。结果 绿原酸在 0 0 2 0 8~ 0 10 4 μg范围内呈线性关系 (r =0 9994 ,n =5 ) ,平均加样回收率为 96 2 3% ,RSD为 0 798%。结论 本方法准确、可行 ,可用于健脾降脂颗粒的质量控制 相似文献
78.
目的:分析用血浆巨细胞病毒(cytomegalovirus,CMV)多聚酶链反应(plymerase chain reaction,PCR)检测结果指导抗CMV干预性治疗的临床意义。方法:1999年8月至2001年7月行异基因造血干细胞移植(hematopoietic stem cell transplantation,HSCT)的所有患者自预处理开始,常规用PCR法检测血浆的CMV-DNA(采用华美公司生产的巨细胞病毒4℃ PCR检测试剂盒),每周1次。其中尚无CMV病的临床表现而检测到血浆CMV阳性的患者89例。随机选取52例阳性患者给予干预性治疗。将上述89例患者分为3组(分别为停止治疗时血浆CMV-PCR转阴组、停止治疗时未转阴组、血浆CMV阳性未治疗组)比较各组CMV病的发生率。CMV病的发生率采用Kaplan-Meier曲线表示,曲线间的比较用Log-Rank(曲线无交叉)或Breslow(曲线交叉)检验,某时点率的比较采用RXC列联表或χ^2检验。结果:100d内CMV病的发生率,在治疗后血浆CMV-PCR由阳性转为阴性组为10.26%,治疗结束时血浆CMV-PCR仍为阳性组为66.67%,血浆CMV-PCR阳性未治疗组为36.24%(P=0.0000)。上述3组中任两组移植后100d CMV病的发生率差异均有显著性。移植后1年时上述3例CMV病累积发生率分别为30.65%、75.00%、42.95%(P=0.0009),治疗未转阴组与治疗转阴组和阳性未治疗组相比,CMV病的发生率明显升高。结论:血浆CMV-PCR检测结果用来指导干预性治疗有一定临床意义。干预性治疗后血浆CMV-DNA仍未转阴者,应考虑换药或联合用药治疗。 相似文献
79.
80.
Steven S Clark Li Zhong Daniele Filiault Sarah Perman Zhibin Ren Michael Gould Xinhai Yang 《Clinical cancer research》2003,9(12):4494-4504
PURPOSE: Perillyl alcohol (POH) displays preventive and therapeutic activity against a wide variety of tumor models, and it has been suggested that this might be associated with the ability of POH to interfere with Ras prenylation. POH also selectively induces G(1) arrest and apoptosis in Bcr/Abl-transformed hematopoietic cells. Because signaling through Ras is necessary for Bcr/Abl transformation, we examined whether POH induces its anti-leukemia effect by inhibiting Ras signaling. EXPERIMENTAL DESIGN: The ability of POH to inhibit posttranslational farnesylation and signaling from Ras as well as signaling through the Raf-Mek-Erk cascade was examined in Bcr/Abl-transformed and mock-transformed cells and related to the anti-leukemia effect of POH. RESULTS: POH does not affect Ras prenylation or Ras activity, but it blocks signaling downstream of Ras by reversing the state of activation of the Erk kinase, Mek. POH affects Mek activity only when it is added to intact cells. Treatment of either cell lysates or of purified Mek with POH has no effect on Mek activity. Inhibition of the Mek-Erk pathway seems to be related to the POH anti-leukemia effect for the following reasons: (a) the concentration of POH needed to block the Erk pathway, as well the kinetics with which POH inhibits this signaling cascade, both correlate with the anti-leukemia effect of POH; (b) both U0126 (a specific Mek inhibitor) and POH induce similar anti-leukemia effects; and (c) mock-transformed hematopoietic cells are simultaneously resistant to POH anti-leukemia effects and inhibition of the Mek-Erk pathway. CONCLUSION: Blocking Mek is sufficient to induce growth arrest and apoptosis in Bcr/Abl-transformed cells; therefore, POH represents a novel small molecule inhibitor of Mek that might be effective for treating Bcr/Abl leukemias. 相似文献